Research and Development (R&D) has been our core focus to transform our company into a truly international one. This is another area where we have already shown our capability. In proprietary research, we have collaborative research agreement with Ciba Specialty Chemicals of Switzerland for a joint research initiative.

In formulation R&D, our Research and Development (R&D) team focuses principally on developing new formulations, predominantly through reverse engineering techniques and on simplifying manufacturing processes and improving cost efficiency. Over the last few years, the team successfully developed a number of hi-tech formulations that include Ultrafen^® Plus - a multi-layer formulation for relief from pain and inflammation, Pretin^®-D - a 24-hour acting formulation for relief from allergic rhinitis with congestion, and Deflux^® DT- a dispersible tablet formulation for prompt relief from nausea and vomiting. These formulations are now commercially available in Bangladesh following regulatory registrations. In addition, we are also developing a number of Active Pharmaceutical Ingredients (APIs) to ensure availability of raw materials across the range of therapeutic classes.

Until now, Beximco Pharma is the only company in Bangladesh to manufacture anti-retroviral drugs complying with the WHO recommended treatment guidelines. More recently, we have added an anti-cancer product in our product portfolio. We also have over eight years of R&D and manufacturing experience in producing highly sophisticated Metered Dose Inhaler (PMDI) products, including salbutamol (albuterol), beclomethasone, salmeterol, salmeterol plus fluticasone, budesonide, ipratropium, tiotropium, Levosalbutamol, ciclesonide inhalers and have emerged as one of the leading pharmaceutical companies in asthma & COPD market in South Asia region. The reverse engineering capability of the R&D team and the drive towards new product development and innovation are central to building a proprietary research operation within Beximco Pharma.